Minnesota Journal of Law, Science & Technology
Volume 9

Issue 1

Article 7

2007

Five Ethical Questions for SCNT Stem Cell Research
Ronald M. Greem

Follow this and additional works at: https://scholarship.law.umn.edu/mjlst

Recommended Citation
Ronald M. Greem, Five Ethical Questions for SCNT Stem Cell Research, 9 MINN. J.L. SCI. & TECH. 131
(2008).
Available at: https://scholarship.law.umn.edu/mjlst/vol9/iss1/7

The Minnesota Journal of Law, Science & Technology is published by the
University of Minnesota Libraries Publishing.

GREEN R. FIVE ETHICAL QUESTIONS FOR SCNT STEM CELL RESEARCH. MINN. J.L. SCI. &
TECH. 2008;9(1):131-144.

Five Ethical Questions for SCNT Stem Cell
Research
Ronald M. Green *
In August 2000, I received a phone call from Michael
West, President and Chief Scientific Officer of Advanced Cell
Technology (ACT), a small Massachusetts biotech company.
West told me that ACT was about to embark on a program of
research involving the use of somatic cell nuclear transfer
(SCNT), also called therapeutic or research cloning, for the
purpose of creating immunologically compatible embryonic
stem cell lines. He wanted to know whether I was interested
in serving as Chair of an Ethics Advisory Board (EAB) that
ACT was setting up to provide guidance for its research.
Thus began an adventure that continues to occupy my
time seven years later. Like all adventures, it has had its
emotional highs and lows: moments of exhilarating
accomplishment and others of seeming failure. Among them:
the year-long collaborative effort of setting up the world’s first
SCNT research egg donor program and watching the first eggs
arrive for cloning experiments; 1 the November 2001
announcement of the creation of the world’s first cloned
human embryo; 2 and then days later, a bitter controversy over
whether the announcement was premature in terms of its
© 2008 Ronald M. Green.
* Ronald Green, Ph.D., is Eunice and Julian Cohen Professor for the
Study of Ethics and Human Values, Dartmouth College; Director, Ethics
Institute, Dartmouth College; Professor, Department of Community and
Family Medicine at the Dartmouth Medical School.
1. Scientists Allege U.S. Losing Lead in Stem Cell Research; Advanced
Cell Technology Generated Stem Cell Embryos in 2003, but Lack of Federal
Funding Hampered Progress, BUS. WIRE, Nov. 23, 2005, http://findarticles.
com/p/articles/mi_m0EIN/is_2005_Nov_23/ai_n15868043.
2. Jose B. Cibelli et al., Rapid Communication: Somatic Cell Nuclear
Transfer in Humans: Pronuclear and Early Embryonic Development, EBIOMED: J. REGENERATIVE MED., Nov. 26, 2001, at 25, 25, http://www.
liebertonline.com/doi/abs/10.1089/152489001753262168; Jose B. Cibelli et al.,
The First Human Cloned Embryo, SCI. AM., Jan. 2002, at 44, 45.
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significance. 3
From 2002 to 2004, the Bush Administration threatened
to ban SCNT research. The Republican-dominated Congress
eliminated the trickle of venture capital funding that kept
ACT afloat. 4 These hostilities forced the termination of the
expensive therapeutic cloning program and impaired ACT’s
ability to meet its payroll expenses, leading some key
researchers to seek positions elsewhere. In February 2004,
there was combined disappointment and excitement when
Korea’s Woo Suk Hwang announced that he had been able to
derive lines of stem cells using the SCNT procedure. 5 The
disappointment derived from the awareness that the Koreans
had accomplished what was just beyond ACT’s reach, given its
cash-starved and politically harassed circumstances. The
excitement came in the “I told you so” moment when Hwang’s
work appeared to vindicate ACT’s commitment to therapeutic
cloning research. Working beyond the reach of the Bush
Administration, the Koreans had done it.
Then, more disappointment and excitement came a year
later when Hwang’s systematic fraud was revealed and his
findings were discredited. 6 This episode tarnished all stem
cell research and heartened its critics. But the goal still
beckoned, and the experience ACT and its EAB had developed
was once again of value. Investors returned and the race was
on.
As I review the highs and lows of this adventure, I am
struck by how many additional small achievements and
setbacks there are to recount. In meeting after meeting, the
EAB has been confronted by the many novel ethical questions
this research involves. It has had to answer these questions
in the context of an ongoing research program, in some cases
with the safety of research participants at issue. This article
details five of the most challenging questions that the EAB
has had to address: (1) what the correct name is for ACT’s

3. News & Comment, “Cloned” Human Embryo Sparks Reaction, 23
TRENDS PHARMACOLOGICAL SCI. 58, 58 (2002).
4. Carol Ezzell, Cloning and the Law, SCI. AM., Jan. 2002, at 51.
5. Woo Suk Hwang et al., Evidence of a Pluripotent Human Embryonic
Stem Cell Line Derived from a Cloned Blastocyst, 303 SCIENCE 1669, 1669
(2004).
6. Lori Gruen, Oocytes for Sale?, 38 METAPHILOSOPHY 285, 304 (2007).
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research; (2) whether SCNT research is ethically appropriate;
(3) what the entity produced by SCNT is called and its moral
status; (4) whether it is ethical to financially compensate
women who provide eggs; and (5) whether there are
alternatives that reduce or eliminate the morally questionable
aspects of SCNT research.
1. WHAT IS THE APPROPRIATE NAME FOR ACT’S
RESEARCH?
It is a measure of how controversial this whole area is
that the seemingly trivial question of what to call ACT’s
research occasions dispute. From the start, ACT’s EAB
identified its program as “therapeutic cloning” research. This
term was already used to distinguish cloning aimed at the use
of SCNT technology to create immunologically compatible
stem cells from reproductive cloning, the use of SCNT to
create a child. Nevertheless, voices were immediately raised
criticizing this name. In its July 2002 report, Human Cloning
and Human Dignity, the Bush-appointed President’s Council
on Bioethics (PCBE) replaced “therapeutic cloning” with the
term “cloning for biomedical research.” 7 It did so for two
reasons.
First, the term was changed because Council
members believed that the distinction between reproductive
and therapeutic cloning was inaccurate, since all cloning
involved the creation or reproduction of a human being. 8
Second, because, in the words of the report, while “[t]he act of
cloning embryos may be undertaken with healing motives . . .
it is not in itself an act of healing or therapy.
The
beneficiaries of any such acts of cloning are, at the moment,
hypothetical and in the future.” 9 Both of these objections are
questionable. The claim that “all cloning is reproductive” 10
reflects a strong position on the nature and moral status of
entities produced by SCNT cloning. The elimination of the
use of the term “therapy” is tendentious because it is quite
obvious that the therapeutic benefits of this research lay in
the future. Nevertheless, these objections are not surprising
from a Council that would ultimately take the unprecedented
7. THE PRESIDENT’S COUNCIL ON BIOETHICS, HUMAN CLONING AND
HUMAN DIGNITY: AN ETHICAL INQUIRY 44–45 (2002).
8. Id. at 44.
9. Id.
10. Id.
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step of proposing to criminalize this whole area of scientific
research by recommending a four-year moratorium on it. 11
2. IS THIS RESEARCH ETHICALLY APPROPRIATE?
That the members of ACT’s EAB chose to provide ethical
guidance for the conduct of this research illustrates that all of
those who signed on to the project believed, in principle, that
therapeutic cloning research can be ethically conducted. That
judgment rested on three main convictions.
First, the EAB believed that therapeutic cloning research
has lifesaving potential and could dramatically address
urgent medical needs. Many of the disease conditions that
remain without adequate therapies or cures are disorders
caused by cell death or degeneration. This includes both
juvenile and late-onset diabetes, Parkinson’s disease,
osteoporosis, skin and bone injuries, heart disease, and a host
of neurological and neuronal disorders and injuries. 12 Stem
cell research offers new approaches to treating these
conditions. But what many regard as the most promising line
of development, human embryonic stem cell research, still
does not resolve the problem of tissue rejection. This rejection
is because stem cells from an embryo are perceived by the
recipient’s body as foreign tissue. 13 Medications could be used
to prevent rejection, but they carry a steep price: increasing
susceptibility to infections and cancers. 14 Therapeutic cloning
promises all of the benefits of embryonic stem cell research
plus a solution to the problem of rejection. 15 By creating cells
or tissues for which the recipient provides the somatic cell
nucleus for the cloning procedure, it is possible to generate
immunologically compatible tissue or organs. 16
The viability of this approach was demonstrated by a
proof-of-principle experiment conducted by ACT scientists

11. Id. at 205.
12. Robert P. Lanza et al., The Ethical Validity of Using Nuclear
Transfer in Human Transplantation, 284 JAMA 3175, 3175 (2000)
[hereinafter Lanza, Ethical Validity].
13. Id.
14. Jennifer Couzin, Gently Soothing a Savage Immune System, 296
SCIENCE 456, 456–57 (2002).
15. Lanza, Ethical Validity, supra note 12, at 3175.
16. Id.
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working with researchers from Harvard, the Mayo Clinic, and
the University of Miami. 17 In this experiment, bovine renal
tissue was created through a cloning procedure that began
with the body cells of one cow and the enucleated egg of a
second cow. 18 Samples of the resulting cloned tissue were
then attached to microtubules and plastic bladders. 19 Some of
these renal constructs were inserted under the skin of the
original cell donor cow while others were inserted under the
skin of control cows that had donated neither the original
somatic cell nor the egg. 20 When subsequently removed from
the animals’ bodies for examination, the constructs inserted
into control cows evidenced rejection and necrosis. 21 The
tissue of the constructs removed from the original cell donor
cow was pink and perfused. 22 Amazingly, these cells also
produced urine that collected in the plastic bladder. 23 Here
were miniature, immunologically compatible kidneys. This
experiment graphically illustrates the scientific promise of
therapeutic cloning research. 24
A second factor supporting EAB’s judgment about the
moral acceptability of this research was its agreement that
the moral status of the entity created by the SCNT procedure
was, at most, identical to a fertilized human egg (or early
embryo). The EAB did not have a moral problem with the
creation of SCNT embryos because it was of the opinion that
sexually produced embryos could be used in potentially
lifesaving research, whether the embryo was left over from
infertility procedures or deliberately created for the purpose.
The EAB believed that if it was permissible to create
supernumerary embryos in in vitro fertilization (IVF) for
reproductive purposes, it was also permissible to create
embryos for lifesaving research. Some EAB members further
believed that the SCNT embryo has even less moral status
17. Robert P. Lanza et al., Generation of Histocompatible Tissues Using
Nuclear Transplantation, 20 NATURE BIOTECHNOLOGY 689 passim (2002).
18. Id. at 694.
19. Id.
20. Id.
21. Id. at 690.
22. Id. at 692.
23. Id.
24. Although this experiment is illustrative, “[b]ecause the cloned cells
were derived from early-staged fetuses, this approach is not an example of
therapeutic cloning and would not be undertaken in humans.” Id. at 689.
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than the early, sexually produced embryo.
Third, and finally, while all the members of the EAB
shared the widely held view that for safety reasons alone it
would be unethical to produce a child by means of cloning, no
member believed this research would significantly hasten the
advent of reproductive cloning or that refraining from this
research would prevent reproductive cloning.
Members
understood that breakthroughs in therapeutic cloning
techniques might contribute to the work of those seeking to
accomplish reproductive cloning, but they believed that
anyone bent on the latter would eventually be able to
accomplish it with or without the help of therapeutic cloning
researchers. To explain through an analogy: abstaining from
therapeutic cloning research in order to prevent reproductive
cloning research would amount to avoiding giving a baby a
bath because of the remote possibility of harming the baby.
3. WHAT SHOULD WE CALL THE ENTITY PRODUCED BY
SCNT (I.E., CLONING) AND WHAT IS ITS MORAL
STATUS?
Is the immediate result of human SCNT (i.e., cloning) a
human embryo? Is it a product of human reproduction, as the
PCBE maintained? If so, does it have the same moral status
(whatever that status might be) as the embryo produced when
a human sperm fertilizes a human egg? Here again we have a
terminological question that conceals powerful moral
disagreements.
To some people, it is obvious that the SCNT unit is
morally equivalent to a human embryo. It has a full
complement of chromosomes as well as the potential to
For these people, it is
develop into an adult being. 25
irrelevant that this potential requires intensive technological
intervention and that it may have developmental potential
significantly inferior to that of a sexually fertilized egg. 26
Embryos acquired from IVF also require intensive
technological intervention, and scientific advances are likely
to significantly reduce the current high mortality of SCNT

25. THE PRESIDENT’S COUNCIL ON BIOETHICS, supra note 7, at 153.
26. Id. at 156.
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units. 27 The mere chance that an entity could become a child,
the critics maintain, should lead one to place it on a par with
the product of fertilization. 28
Not everyone agrees. During the EAB’s initial debates,
one of its scientist members surprised the other members by
launching into what can only be called an “ode to
fertilization.” She said that while working in reproductive
medicine for many years, she never lost her sense of awe at
watching a sperm fertilize an egg. But she insisted that for
her, the SCNT process had none of this sanctity. It was an
entirely artificial process and it could be arrested for research
purposes as readily as it had been begun. In a subsequent
letter to a scientific journal, this colleague proposed a new
name for the product of SCNT. 29 She would call it an
“ovasome,” or egg-body. 30 This term, she believed, better
described the very limited moral importance of what SCNT
researchers were doing. 31
Whatever this entity is called, and however its moral
status is assessed in relation to the sexually produced embryo,
in no case would it rank higher. Hence, individuals willing to
use or create embryos for research purposes should be willing
to support therapeutic cloning research. For a more extensive
treatment of this issue and defense of using human embryos
in lifesaving research or research of outstanding biomedical
value, one might look at the 1994 Report of the National
Institute of Health Human Embryo Research Panel. 32
4. IS IT ETHICAL TO PAY WOMEN TO PROVIDE EGGS
FOR THIS RESEARCH?
Therapeutic cloning research requires an abundant
supply of eggs. In the case of Dolly the sheep, it took 277
nuclear transfers to produce one viable embryo. 33 While
27. Id. at 137.
28. Id. at 152–57.
29. Ann A. Kiessling, In the Stem-cell Debate, New Concepts Need New
Words, 413 NATURE 453, 453 (2001).
30. Id.
31. Id.
32. NAT’L INST. OF HEALTH, REPORT OF THE HUMAN EMBRYO RESEARCH
PANEL (1994).
33. DEP’T OF HEALTH, STEM CELL RESEARCH: MEDICAL PROGRESS WITH
RESPONSIBILITY
24
(2000),
available
at
http://www.dh.gov.uk/
PublicationsAndStatistics/Publications/PublicationsPolicyAndGuidance/Publ
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technical advances may reduce this ratio, a viable therapeutic
cloning research program still requires over a dozen egg
donors to have even a chance at producing a stem cell line. 34
Egg donation requires the use of powerful drugs that
stimulate a woman’s ovaries to produce multiple mature
follicles instead of the single fertilizable egg of a normal
cycle. 35 Although some studies have suggested that these
medications do not create significant risks for healthy women,
the safety of their repeated use has not been confirmed. 36 The
non-aqueous drugs are painful to administer (requiring
repeated injection directly into the buttocks) and they can
cause the intense emotional reactions usually associated with
hormonal irregularities. 37 There is also a very small (and
largely preventable) risk of ovarian hyperstimulation, a life
threatening overreaction to the drugs. 38 In view of all these
risks and burdens, why should women volunteer to provide
eggs for research unless they are adequately compensated?
The experience with reproductive egg donation is instructive.
In the United States, reproductive egg donors are paid
varying but substantial sums of money and there is an
adequate supply of donors. 39 Great Britain, in contrast,
prohibits payment for reproductive and research donors and
has suffered a virtual standstill in supply. 40 In an effort to
address this problem, the Human Fertilisation and
Embryology Authority (HFEA), the agency that provides
oversight for all infertility medicine and embryo research in
icationsPolicyAndGuidanceArticle/fs/en?CONTENT_ID=4065084&chk=Igqu.
34. Alan Boyle, Researchers Customize Stem-Cell Lines, MSNBC, May
19, 2005, http://www.msnbc.msn.com/id/7904332/.
35. Robert E. Bristow & Beth Y. Karlan, Ovulation Induction, Infertility,
and Ovarian Cancer Risk, 66 FERTILITY & STERILITY 499, 499 (1996).
36. Id.
37. Ronald M. Green, Open Forum: It’s Right to Pay Women Who Give
Their Eggs for Research, S.F. CHRONICLE, July 19, 2005, at B7 [hereinafter
Green, It’s Right to Pay Women].
38. Ronald M. Green, The Ethical Considerations, SCI. AM., Jan. 2002,
at 48, 49 [hereinafter Green, Ethical Considerations].
39. Id.; see also Gruen, supra note 6, at 296. But see id. at 285
(reporting a shortage of eggs in California following the 2004 ballot initiative
prohibiting sale of oocytes for research purposes).
40. Press Release, Newcastle Univ. Press Office, ‘Egg Sharing’ Go-Ahead
for Stem Cell Researchers (July 27, 2006), available at http://www.ncl.ac.uk/
press.office/press.release/content.phtml?ref=1154008083.
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that country, has permitted egg-sharing programs, whereby
women undergoing IVF can receive discounted services for
offering some of their eggs to other women who need them for
reproductive purposes. 41 Last year, the HFEA expanded this
permission to include research egg donation. 42
In 2005, an influential report by a committee of the
National Academy of Sciences recommended against payment
(beyond out-of-pocket expenses) for research egg donation. 43
In the wake of this, several states, including California and
Massachusetts, passed laws prohibiting payment for eggs for
research. 44 Because both states have significant public or
private commitments to therapeutic cloning research, these
bans have had the effect of preventing this research from
starting. Since the passage of the Massachusetts law, despite
expressions of interest from over one hundred women in
response to advertising, ACT has been able to secure only one
voluntary donor. 45 This compares to over eighty women who
donated eggs under the previous paid research donor
program.
Why, if payment is so clearly needed to facilitate
research, do so many authorities oppose it? Some of the
answers given to this question do not withstand close scrutiny
and may even proceed from sexist premises. The view that
women can be paid for eggs for reproductive but not research
purposes may reflect the belief that maternally related
sacrifices are somehow proper to women, whereas a
commitment to science research is not. Some fear that poor
women and women of color will be disproportionately
attracted to research egg donation since the mother’s genetics
and accomplishments do not matter in this sphere as they do
in the reproductive one. 46 The concern is that such payments
may constitute an “undue influence,” compromising women’s
ability to provide free and informed consent and risking their

41. Id.
42. Id.
43. NAT’L ACAD. OF SCI, GUIDELINES FOR HUMAN EMBRYONIC STEM
CELL RESEARCH 83 (2005).
44. Green, It’s Right to Pay Women, supra note 37.
45. Bijal Trivedi, Researchers Detour Around Stem-Cell Rules: Thwarted
by Regulations on Egg Donation for Research, Scientists Craft New Ways to
Manufacture Embryos, CHRONICLE OF HIGHER EDUC., Oct. 5, 2007, at 12.
46. Gruen, supra note 6, at 303.
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health. 47 But it can also be asked why women should be
protected from their own decision-making and whether such
attitudes reflect unjustified paternalism—or patriarchalism. 48
In a world where normal research volunteers are often paid
for their participation in risky research, why should women be
denied similar opportunities?
An unpublished review of reports from the ACT research
egg donors indicates that the more than eighty women who
served in this capacity tended to express two equally
significant reasons for doing so: (1) a desire to contribute to
stem cell research and (2) a desire for the money. Many of
these women reported having family members who suffered
from diseases like diabetes that stem cell therapies might
address. In view of this, the prohibition on payment becomes
even more problematic. Why should women who wish to
contribute to research, but who need a financial incentive to
overcome their natural reluctance to submit to a demanding
drug regimen, be held to a purely altruistic standard?
Seven years ago, ACT’s EAB asked all these questions
regarding compensation for egg donors. The EAB discussed—
and rejected—egg sharing on the grounds that it unwisely
mixes the sensitive issue of infertility treatment with research
donation. If a women’s reproductive quest fails, will she come
to regret and resent her decision to donate eggs for research
purposes? Will she harbor the view that researchers took the
best of her eggs? The EAB also carefully developed guidelines
to protect women from harm. 49 These guidelines covered
everything from age limits, psychological testing, and
reproductive history to safe estradiol levels. In the end, the
EAB concluded that a well-developed program was ethically
and scientifically appropriate. It is distressing that seven
years down the line, as programs around the country renew
their attention to therapeutic cloning, these lessons need to be
learned all over again.
47. NAT’L ACAD. OF SCI., supra note 43, at 71.
48. Green, Ethical Considerations, supra note 38, at 49.
49. See Press Release, Advanced Cell Tech., Statement by the Ethics
Advisory Board of Advanced Cell Technology (June 2, 2002), available at
http://www.advancedcell.com/press-release/statement-by-the-ethics-advisoryboard-of-advanced-cell-technology) (“The ACT EAB has also established a
rigorous program of informed consent for women who donate eggs for human
therapeutic cloning research.”).
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5. CAN THE SCNT PROCEDURE BE ALTERED TO
REDUCE OR ELIMINATE ITS MORALLY QUESTIONABLE
ASPECTS?
Several technical ideas have been advanced to address
some of the ethical questions raised by SCNT technology. For
example, it has been proposed to use animal oocytes to replace
the use of human eggs in the cloning procedure. 50 There have
been reports of success with this approach, although they
have not been replicated. 51 Unfortunately, although the use
of animal oocytes eliminates the problems associated with
human egg donors, it raises additional problems associated
with the production of animal-human chimeras or what have
been termed “cybrids.” 52 These include concerns ranging from
the possibility that the resulting stem cells may be unsuitable
for transplant and could introduce animal DNA or pathogens
into the human population to the nightmarish possibility that
chimeric embryos might be diverted for reproductive
purposes. 53 Ethically, this approach raises more questions
than it answers.
A more radical change in the SCNT procedure has
recently been proposed as a way of eliminating the moral
discomfort with human embryonic stem cell researched
experienced by those who regard the early embryo as a human
being. This proposal, known as Altered Nuclear Transfer
(ANT) was made by William Hurlbut, a member of the
It involves using the standard SCNT cloning
PCBE. 54
procedure for the purpose of stem cell derivation—with one
notable difference. In ANT, the somatic cell used for cloning
is first genetically altered so as to impair the resulting SCNT
Hurlbut states that
unit’s developmental capability. 55
50. Michael Schirber, A Dash for Hare Eggs, 311 SCIENCE 317 (2006).
51. Id.
52. Id.; see also Constance Holden, Report Backs Interspecies Lines, 316
SCIENCE 1683 (2007).
53. Schirber, supra note 50, at 317.
54. William B. Hurlbut, Altered Nuclear Transfer as a Morally
Acceptable Means for the Procurement of Human Embryonic Stem Cells
(2004)
(working
paper),
available
at
http://www.bioethics.gov/background/hurlbut.html.
55. Alexander Meissner & Rudolf Jaenisch, Generation of Pluripotent
NT-ES Cells from Cloned Cdx2 Deficient Blastocysts, 439 NATURE 212, 212
(2006). This was done experimentally by impairing the Cdx2 gene that is
responsible for placental development. Id. Lacking a functioning copy of
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because this modification is undertaken before the clonal
embryo is even created, the resulting entity would have “no
inherent principle of unity, no coherent drive in the direction
of the mature human form, and no claim on the moral status
due to a developing human life.” 56 He prefers the term
“clonal” or “biological artifacts” for these entities. 57
Unfortunately, it is by no means clear that many of the
people who morally equate the early human embryo with a
full human being will be satisfied with this strategy for
producing immunologically compatible stem cells.
ANT
embryos develop normally until Cdx2 function is required, at
which point they die. 58 This suggests that people with a high
estimate of the status of early nascent human life might
reasonably interpret this procedure as involving the
deliberate creation of an impaired human being in order to
justify destroying it. In effect, they would see it as doing two
wrongs in order to do a right.
A simple example supports this objection. If the early
embryo is fully a human being, as the opponents of embryo
destruction believe, how does ANT differ morally from the
deliberate creation of an anencephalic infant as an organ
donor? Lacking a cerebrum, this child can also be said to have
“no inherent principle of unity, no coherent drive in the
direction of the mature human form, and no claim on the
moral status due to a developing human life.” 59 If we find
such a proposal morally repugnant, it is not clear why an
analogous impairment imposed on a “human being” at a much
earlier stage is acceptable.
CONCLUSION
Despite the serious reverses represented by the Korean
scandal, therapeutic cloning remains one of the most
promising biomedical technologies before us. As my tenure as
Chair of ACT’s EAB indicates, I believe that none of the
this gene, the NT unit cannot implant and develop. If necessary, it might be
possible to turn the Cdx2 gene on again in the resulting stem cells.
56. Hurlbut, supra note 54.
57. THE PRESIDENT’S COUNCIL ON BIOETHICS, supra note 7, at 275.
58. Douglas A. Melton et al, Altered Nuclear Transfer in Stem-Cell
Research—A Flawed Proposal, 351 NEW ENG. J. MED. 2791, 2791 (2004).
59. Hurlbut, supra note 54.
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ethical concerns resident in these five questions constitutes a
reason for refusing to go forward with this research. Whether
we call the entity created by SCNT an embryo or an SCNT
unit, that creation need not be given more—and probably
should be given somewhat less—moral weight to it than is
given to the early human embryo, which can responsibly be
used to derive stem cell lines. Payment for research oocytes
seems to be fully justified and does not raise problematic,
long-term issues. Some people fear that the successful
development of therapeutic cloning will create a vast market
in human eggs that will lead to the exploitation of poor
women. 60 However, several promising technologies are on the
horizon, including in vitro egg maturation and the
development of oocytes from stem cells themselves that will
obviate the need to call on large populations of egg donors. 61
Furthermore, therapeutic cloning is a “transitional” form of
Once scientists better understand which
research. 62
components of egg cytoplasm remodel a cell’s nuclear DNA in
the cloning context, they can use these purified cytoplasmic
factors
for
direct
cellular
dedifferentiation
and
reprogramming.
All of this suggests that research should be furthered.
States like California and Massachusetts, where therapeutic
cloning research is permissible, should repeal the bans on
adequate compensation for research egg donors. 63 Congress
should also abandon its previous efforts to criminalize this
research. 64
Seven years ago, when I accepted the leadership of ACT’s
EAB, I nourished the hope that we would see clonally
60. See, e.g., Judy Norsigian, Egg Donation for IVF and Stem Cell
Research: Time to Weigh the Risks to Women’s Health, DIFFERENT TAKES
(Hampshire College Population & Development Program) Spring, 2005, at 1,
3; Diane Beeson & Abby Lippman, Egg Harvesting for Stem Cell Research:
Medical Risks and Ethical Problems, 13 REPROD. BIOMEDICINE 573, 573, 575
(2006).
61. Nicholas Wade, Pennsylvania Researchers Turn Stem Cells to Egg
Cells, N.Y. TIMES, May 2, 2003, at A28.
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produced stem cells within a few years. We almost did. If it
had not been for continual political meddling, that hope might
have been realized. It is now time for good science and good
research ethics, not politics, to shape the future.

